Want to see TSE:SONA full AI Analyst Report?
SONA Stock Chart & Stats
C$0.31
C$0.01(4.84%)
At close: 4:00 PM EDT
C$0.31
C$0.01(4.84%)
Day’s Range― - ―
52-Week RangeC$0.26 - C$0.84
Previous CloseN/A
Volume13.05K
Average Volume (3M)124.26K
Market Cap
C$32.03M
Enterprise ValueC$32.88M
Total Cash (Recent Filing)C$52.76K
Total Debt (Recent Filing)C$328.87K
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding114,375,250
10 Day Avg. Volume87,178
30 Day Avg. Volume124,263
Financial Highlights & Ratios
PEG Ratio-2.89
Price to Book (P/B)-1.80K
Price to Sales (P/S)0.00
P/FCF Ratio-35.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Gold Nanorod TechnologySona’s core IP in gold nanorods targets diagnostics and life-science labeling—a specialized, high-value niche. Durable intellectual property and a focused product offering can create sustainable differentiation versus commodity suppliers and support long-term commercial partnerships in diagnostic workflows.
Improving Loss Profile Versus Earlier PeakThe company has materially reduced losses and cash consumption from its 2021 peak, indicating progress on cost control and operational discipline. Sustained narrowing of losses improves runway and reduces near-term dilution risk if continued over the next several quarters.
Modest Absolute Debt BurdenWith only modest reported debt in absolute dollars, Sona has limited fixed interest obligations, which reduces immediate solvency strain. Lower contractual leverage provides flexibility to prioritize investment in commercialization or R&D without heavy near-term debt service.
Bears Say
No Reported RevenueThe company has no reported revenue, leaving commercial validation unproven and making future growth dependent on successful product commercialization or licensing. Absent sales, long-term viability hinges on raising capital or achieving product-market fit, increasing execution risk.
Persistent Cash Burn And Operating LossesSustained negative operating and free cash flow with multi‑million TTM losses signals ongoing funding needs. Continued cash burn erodes liquidity and forces reliance on external financing, which can dilute shareholders and constrain strategic investments over the medium term.
Shift To Negative Shareholders' EquityThe move to negative equity increases balance-sheet fragility and reduces lender and investor comfort. Negative equity complicates leverage metrics, may limit financing options or increase cost of capital, and heightens the risk that future funding requires significant dilution.
Sona Nanotech Inc News
SONA FAQ
What was Sona Nanotech Inc’s price range in the past 12 months?
Sona Nanotech Inc lowest stock price was C$0.26 and its highest was C$0.84 in the past 12 months.
What is Sona Nanotech Inc’s market cap?
Sona Nanotech Inc’s market cap is C$32.03M.
When is Sona Nanotech Inc’s upcoming earnings report date?
Sona Nanotech Inc’s upcoming earnings report date is Sep 24, 2026 which is in 48 days.
How were Sona Nanotech Inc’s earnings last quarter?
Sona Nanotech Inc released its earnings results on Jun 29, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.
Is Sona Nanotech Inc overvalued?
According to Wall Street analysts Sona Nanotech Inc’s price is currently Overvalued.
Does Sona Nanotech Inc pay dividends?
Sona Nanotech Inc does not currently pay dividends.
What is Sona Nanotech Inc’s EPS estimate?
Sona Nanotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sona Nanotech Inc have?
Sona Nanotech Inc has 114,375,250 shares outstanding.
What happened to Sona Nanotech Inc’s price movement after its last earnings report?
Sona Nanotech Inc reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sona Nanotech Inc?
Currently, no hedge funds are holding shares in TSE:SONA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sona Nanotech Inc
Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic test designed to detect the SARS-CoV-2 spike protein antigen in saliva from individuals suspected of having the virus. The company also offers Gemini and Omni gold nanorods, with the latter specifically engineered for medical uses, in addition to providing contract services. These versatile products are utilized in a wide array of applications, such as targeted drug delivery, environmental and food safety monitoring, cellular visualization, cancer therapy, liposuction treatments, and diagnostic tools for medical, consumer, military, and veterinary sectors.
Technical Analysis
BioMark Diagnostics
―
Eastwood Bio-Medical Canada
―
StageZero Life Sciences Ltd
―
Medmira
―
ZYUS Life Sciences
―